Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 11,156 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort study Clear all
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP).

NCT01988584
View directory record Official record
Conditions
Cerebral Palsy
Interventions
umbilical cord blood (hUCB) cells, Saline Infusion (Placebo), bone marrow derived mononuclear cells (BMMNCs)
Biological · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
2 Years to 10 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 29, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}

NCT02358343
View directory record Official record
Conditions
Depression, End Stage Renal Disease
Interventions
Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Albuquerque, New Mexico • Dallas, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 29, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

NCT03822117
View directory record Official record
Conditions
Solid Tumor Malignancy
Interventions
Pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
44
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 29, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime

NCT02532140
View directory record Official record
Conditions
Healthy
Interventions
WCK 5107 250 mg to 2000 mg, Cefepime 2000 mg, WCK 5107 1000/2000 mg with Cefepime 2000 mg combination, Placebo
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 29, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

NCT01592110
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone-SABER, ZX003:risperidone-SABER and the DosePro System
Drug · Other
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 29, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

NCT00655655
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 29, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

NCT01769508
View directory record Official record
Conditions
HER2 Positive Esophagogastric Cancer
Interventions
5-Fluorouracil, Oxaliplatin, Lapatinib, Radiation Therapy
Drug · Radiation
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Fort Myers, Florida • Orlando, Florida • Pensacola, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 29, 2026, 5:01 PM EDT
Recruiting Not applicable Interventional

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

NCT05313191
View directory record Official record
Conditions
CNS Cancer, Head and Neck Cancer, GI Cancer, Gynecologic Cancer, Prostate Cancer, Thoracic Cancer, Breast Cancer
Interventions
Pencil Beam Scanning Proton Therapy
Radiation
Lead sponsor
The New York Proton Center
Other
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 29, 2026, 5:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Short Term Outcomes of Heavy-weight Versus Medium-weight Synthetic Mesh

NCT06409091
View directory record Official record
Conditions
Hernia, Ventral, Hernia Incisional
Interventions
Medium weight or Heavy weight mesh
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
1,496 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 29, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease

NCT04365218
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
MEDI8367, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 29, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

NCT07310901
View directory record Official record
Conditions
Obese But Otherwise Healthy Participants
Interventions
CRB-913, Placebo
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Chandler, Arizona • Rancho Cucamonga, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 29, 2026, 5:01 PM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

NCT06603844
View directory record Official record
Conditions
Solid Tumor
Interventions
CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibody
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 29, 2026, 5:01 PM EDT
Terminated No phase listed Observational

Split Cohort Trial Comparing IVF Outcomes After the Use of Testicular vs. Ejaculated Sperm for ICSI

NCT03483298
View directory record Official record
Conditions
Infertility
Interventions
ICSI
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
7 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 29, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

NCT02737787
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer, Recurrent Ovarian Cancer
Interventions
WT1 Vaccine, Nivolumab, NY-ESO-1 Vaccine
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 29, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

NCT02243306
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 29, 2026, 5:01 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

NCT03787095
View directory record Official record
Conditions
HIV Infections
Interventions
Cemiplimab, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 29, 2026, 5:01 PM EDT
Terminated No phase listed Observational

Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study

NCT07479381
View directory record Official record
Conditions
Colorectal Cancer (Diagnosis)
Interventions
Not listed
Lead sponsor
Harbinger Health
Industry
Eligibility
45 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 29, 2026, 5:01 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

NCT06597565
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Gemcitabine, ACR-368
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 29, 2026, 5:01 PM EDT
Completed No phase listed Observational

A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)

NCT05068609
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Mount Laurel, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 29, 2026, 5:01 PM EDT
Completed Phase 1Phase 2 Interventional

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

NCT03377387
View directory record Official record
Conditions
Breast Cancer
Interventions
Capecitabine, Neratinib, EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30
Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 5:01 PM EDT
Active, not recruiting Phase 2 Interventional

Food: A Three-Arm Study Examining Food Insecurity Interventions

NCT01603316
View directory record Official record
Conditions
Cancer Patients
Interventions
surveys, Focus groups
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
10
States / cities
Brooklyn, New York • Jamaica, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 29, 2026, 5:01 PM EDT
Not listed Phase 2 Interventional

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

NCT05223816
View directory record Official record
Conditions
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Interventions
VG161, Nivolumab Injection [Opdivo]
Drug
Lead sponsor
Virogin Biotech Canada Ltd
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 29, 2026, 5:01 PM EDT
Completed No phase listed Observational

Vitamin D Replacement in Nonalcoholic Fatty Liver Disease

NCT03084328
View directory record Official record
Conditions
Nonalcoholic Fatty Liver
Interventions
Vitamind D
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
48 participants
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 29, 2026, 5:01 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

NCT05844293
View directory record Official record
Conditions
FXI
Interventions
FXI-GalNAc-siRNA, Placebo
Drug · Other
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Creve Coeur, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 29, 2026, 5:01 PM EDT